title: No requirement for V(D)J recombination in p53-deficient thymic lymphoma.
abstract: The p53 tumor suppressor is activated in response to a variety of cellular stress signals, although specific in vivo signals that trigger tumor suppression are unknown. In mouse thymocytes, where p53 inactivation leads to tumorigenesis, several observations suggest that V(D)J recombination of T-cell receptor (TCR) loci could provide a DNA damage signal triggering p53-dependent apoptosis and tumor suppression. Inactivation of p53 would allow V(D)J driven mutation of additional cancer genes, facilitating tumorigenesis. Here, we show that mice with a p53 deficiency in thymocytes and unable to carry out V(D)J recombination are not impaired in the development of thymoma. Recombination-activating gene (RAG) deficiencies were introduced into both p53-/- mice and TgTDeltaN transgenic mice, a strain in which 100% of the mice develop thymoma due to thymocyte-specific inactivation of p53 by a simian virus 40 T-antigen variant. V(D)J recombination was dispensable for tumorigenesis since thymomas developed with or without the RAG-1 or RAG-2 gene, although some delay was observed. When V(D)J recombination was suppressed by expression of rearranged TCR transgenes, 100% of the TgTDeltaN mice developed thymoma, surprisingly with reduced latency. Further introduction of a RAG deficiency into these mice had no impact on the timing or frequency of tumorigenesis. Finally, karyotype and chromosome painting analyses showed no evidence for TCR gene translocations in p53-deficient thymomas, although abundant aneuploidy involving frequent duplication of certain chromosomes was present. Thus, contrary to the current hypothesis, these studies indicate that signals other than V(D)J recombination promote p53 tumor suppression in thymocytes and that the mechanism of tumorigenesis is distinct from TCR translocation oncogene activation.
authors.affiliation: Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill Medical School, Chapel Hill, North Carolina 27599, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Liao
authors.forename: X X
authors.initials: XX
authors.lastname: Zhang
authors.forename: R
authors.initials: R
authors.lastname: Hill
authors.forename: J
authors.initials: J
authors.lastname: Gao
authors.forename: M B
authors.initials: MB
authors.lastname: Qumsiyeh
authors.forename: W
authors.initials: W
authors.lastname: Nichols
authors.forename: T
authors.initials: T
authors.lastname: Van Dyke
mesh_terms: D000818:Animals; D002869:Chromosome Aberrations / Q000235:genetics; D004268:DNA-Binding Proteins / Q000502:physiology; D015329:Gene Rearrangement, T-Lymphocyte; D018398:Homeodomain Proteins; D051379:Mice; D008810:Mice, Inbred C57BL; D016513:Mice, SCID; D008822:Mice, Transgenic; D011948:Receptors, Antigen, T-Cell / Q000235:genetics; D013945:Thymoma / Q000235:genetics*; D013953:Thymus Neoplasms / Q000235:genetics*; D019076:Transgenes; D014178:Translocation, Genetic; D016159:Tumor Suppressor Protein p53 / Q000172:deficiency / Q000235:genetics*
chemical_list: D004268:DNA-Binding Proteins; D018398:Homeodomain Proteins; C499308:Rag2 protein, mouse; D011948:Receptors, Antigen, T-Cell; D016159:Tumor Suppressor Protein p53; C064655:V(D)J recombination activating protein 2; C064658:RAG-1 protein